Job title: SVP, Immunology
Philip Ashton-Rickardt is an esteemed immunologist who was on the faculty at the University of Chicago and held the Chair in Immunology at Imperial College London. He has published many reviewed papers in over 30 academic journals (including Cell, Science, Immunity and Nature Immunology). Many of his basic findings on T lymphocytes have been incorporated into leading immunology textbooks and he is the inventor on 6 patents. He has served as an editor for several academic journals and has been a member of many grant review boards throughout the world. Philip’s work on T lymphocytes has been recognized by his peers through the award of tenure from The University of Chicago and by his fellow citizens through the award of the Early Career Award for Scientists and Engineers from President Bill Clinton. In 2017, Philip and his family returned to live in Boston where he focused his energies on building Smith Therapeutics around immunotherapy in neurodegenerative disease such as Alzheimer’s, Parkinson’s and ALS. Philip is the inventor of CAR-Treg therapy targeted to brain glial cells to shut down neuroinflammation, which is a cause of all neurodegenerative disease. On October 1st 2019, Smith Therapeutics was acquired by AZTherapies, a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative disease. Philip has joined AZTherapies to advance the CAR-Treg program into the clinic for the treatment of rare and common neurodegenerative diseases.
Engineered T Regulatory Cell Products to Treat Neurodegenerative Diseases 2:00 pm
AZTherapies is developing off-the-shelf CAR-T regulatory cell therapies (CAR-Treg) to treat high profile neurodegenerative diseases (NDD) including Alzheimer’s and Parkinson’s as well as rare diseases such as Amyotrophic lateral sclerosis (ALS). Inflammation is now recognized as the common thread running through all NDD, that results in neuronal death and disease Our CAR-Treg platform targets brain…Read more
day: Day One